Adverse Effects and Safety of Etirinotecan Pegol, a Novel Topoisomerase Inhibitor, In Cancer Treatment: A Systematic Review

Mohamad Samare-Najaf, Ali Samareh, Navid Jamali, Ali Abbasi, Cain C. T. Clark, Majid Jafari Khorchani, Fatemeh Zal

    Research output: Contribution to journalReview articlepeer-review

    11 Downloads (Pure)

    Abstract

    Background: Due to the increasing prevalence of cancer and the inadequacy of current therapies, the development of novel antitumor pharmaceutics with higher efficacies and lower adverse effects is considered a fundamental tenet of contemporary cancer management. Poly-Ethylene-Glycol (PEG) attachment is a novel pharmaceutical technology to improve the efficacy and safety of chemotherapies. Etirinotecan Pegol (EP), also known as NKTR-102, is the PE-Gylated form of Irinotecan (CPT-11), which causes cancer cell apoptosis by inhibiting the topoisomerase I enzyme. Objective: The present study reviews and evaluates various reports of the EP’s anti-tumor activity in various cancers. Data Source: Studies were identified using the Scopus database, with no exclusions. The search terms included Etirinotecan Pegol and NKTR-102, which yielded 125 articles (66 and 59 articles, respectively). In addition, the clinicaltrials.gov website was used to find ongoing studies, which re-sulted in the addition of two studies. Study Eligibility Criteria: Subsequently, we excluded studies that were published in languages other than English, duplicate articles, and studies with no data. Results: This systematic review clarifies that EP possesses numerous advantages over many other medications, such as safety, efficacy, increased half-life, increased health-related quality of life, increased overall survival, increased progression-free survival, and decreasing the adverse events in the treatment of various cancers. Conclusion: Therefore, Etirinotecan Pegol may represent a major contribution to the treatment of various cancers in the future.

    Original languageEnglish
    Pages (from-to)234-243
    Number of pages10
    JournalCurrent Cancer Therapy Reviews
    Volume17
    Issue number3
    Early online date1 Feb 2021
    DOIs
    Publication statusPublished - Aug 2021

    Funder

    This article was commissioned by the Shiraz University of Medical Sciences, Shiraz, Iran.

    Keywords

    • Cancer
    • Chemotherapy
    • Clinical trials
    • Drug safety
    • Topoisomerase inhibitors
    • Toxicology

    ASJC Scopus subject areas

    • Molecular Medicine
    • Oncology
    • Cancer Research

    Fingerprint

    Dive into the research topics of 'Adverse Effects and Safety of Etirinotecan Pegol, a Novel Topoisomerase Inhibitor, In Cancer Treatment: A Systematic Review'. Together they form a unique fingerprint.

    Cite this